These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Reovirus - possible therapy of cancer. Figova K; Hrabeta J; Eckschlager T Neoplasma; 2006; 53(6):457-62. PubMed ID: 17167712 [TBL] [Abstract][Full Text] [Related]
9. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors. Kapadia R; Coffey MC Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221 [TBL] [Abstract][Full Text] [Related]
10. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Shmulevitz M; Marcato P; Lee PW Oncogene; 2005 Nov; 24(52):7720-8. PubMed ID: 16299532 [TBL] [Abstract][Full Text] [Related]
11. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Harrington KJ; Vile RG; Melcher A; Chester J; Pandha HS Cytokine Growth Factor Rev; 2010; 21(2-3):91-8. PubMed ID: 20223697 [TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS BMC Cancer; 2011 Jun; 11():221. PubMed ID: 21645351 [TBL] [Abstract][Full Text] [Related]
14. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857 [TBL] [Abstract][Full Text] [Related]
15. Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors. RodrÃguez Stewart RM; Berry JTL; Berger AK; Yoon SB; Hirsch AL; Guberman JA; Patel NB; Tharp GK; Bosinger SE; Mainou BA J Virol; 2019 Dec; 93(23):. PubMed ID: 31511390 [TBL] [Abstract][Full Text] [Related]
16. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer. Carew JS; Espitia CM; Zhao W; Kelly KR; Coffey M; Freeman JW; Nawrocki ST Cell Death Dis; 2013 Jul; 4(7):e728. PubMed ID: 23868061 [TBL] [Abstract][Full Text] [Related]
17. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture. Shmulevitz M; Lee PW Methods Mol Biol; 2012; 797():163-76. PubMed ID: 21948476 [TBL] [Abstract][Full Text] [Related]
18. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report. Kolb EA; Sampson V; Stabley D; Walter A; Sol-Church K; Cripe T; Hingorani P; Ahern CH; Weigel BJ; Zwiebel J; Blaney SM Pediatr Blood Cancer; 2015 May; 62(5):751-8. PubMed ID: 25728527 [TBL] [Abstract][Full Text] [Related]
19. Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts. Hingorani P; Zhang W; Lin J; Liu L; Guha C; Kolb EA Cancer; 2011 Apr; 117(8):1764-74. PubMed ID: 21472724 [TBL] [Abstract][Full Text] [Related]
20. Noncanonical Cell Death Induction by Reassortant Reovirus. RodrÃguez Stewart RM; Raghuram V; Berry JTL; Joshi GN; Mainou BA J Virol; 2020 Oct; 94(22):. PubMed ID: 32847857 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]